EUVIMEDEUVIMED entdecken
Open Access

Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation

Kerollos Nashat Wanis, Henry M Kuerer, Susie X Sun, Kelly K Hunt, Alexa C Glencer, Mediget Teshome, Anthony Lucci, Roi Weiser, Helen Johnson, Benjamin D Smith, Angelica M Gutierrez, Simona F Shaitelman und 1 weitere

JAMA Network Open · 25.06.2024 · 7 (6) · e2418486

DOI: 10.1001/jamanetworkopen.2024.18486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.06.2024. Verfasst von Kerollos Nashat Wanis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, Texas. Hauptthemen laut MEDLINE: Breast Neoplasms, Mastectomy, Segmental. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCRR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Although most women with BRCA- associated breast cancer choose bilateral mastectomy, current guidelines support breast-conserving therapy as an option. As the indications for genetic testing expand and targeted therapies emerge, understanding the outcomes of breast-conserving therapy in the population of patients choosing breast conservation is important.

Objective

To describe the clinical outcomes of women with BRCA -associated breast cancer who were treated with breast-conserving therapy, including the risks of ipsilateral and contralateral cancer events and bilateral mastectomy-free survival. Design, Setting, and Participants This cohort study conducted at a single-institution academic national comprehensive cancer center included 172 women identified from a prospectively maintained database who had pathogenic BRCA1/2 variants and were treated with breast-conserving therapy from January 1, 1977, to December 31, 2021. Main Outcomes and Measures Clinical and pathologic characteristics for patients with BRCA1 and BRCA2 were compared, and estimates of overall survival, bilateral mastectomy-free survival, distant disease-free survival, risk of ipsilateral breast cancer, and risk of contralateral cancer were computed.

Results

The cohort included 172 women (mean [SD] age, 47.1 [11.7] years), with 42 (24.4%) receiving a diagnosis of breast cancer prior to 40 years of age. Compared with BRCA2 variant carriers (80 [46.5%]), women with BRCA1 variants (92 [53.5%]) were younger at breast cancer diagnosis and tended to have more advanced tumors, which were more likely to be hormone receptor negative and higher grade. At a median follow-up of 11.8 years (IQR, 5.7-18.2 years), estimates of 10-year survival and risk were: overall survival, 88.5% (95% CI, 83.1%-94.2%); bilateral mastectomy-free survival, 70.7% (95% CI, 63.3%-78.9%); risk of an ipsilateral breast cancer event, 12.2% (95% CI, 5.8%-18.2%); and risk of contralateral cancer, 21.3% (95% CI, 13.3%-28.6%). Risks continued to increase after 10 years of follow-up. Conclusions and Relevance In this cohort study, although women with breast cancer and pathogenic BRCA1/2 variants treated with breast-conserving therapy had above-average risks of ipsilateral and contralateral breast cancer events, most did not have another cancer event and remained bilateral mastectomy free. These findings may be useful for informing patients with BRCA variants choosing breast conservation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMastectomy, SegmentalHumansFemaleMiddle AgedAdultBRCA2 ProteinBRCA1 ProteinCohort StudiesTreatment OutcomeDisease-Free Survival

Substanzen

BRCA2 ProteinBRCA2 protein, humanBRCA1 ProteinBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgical Oncology, MD Anderson Cancer Center, Houston, Texas.
  • Department of Breast Radiation Oncology, MD Anderson Cancer Center, Houston, Texas.
  • Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, Texas.

Förderung

  • NCI NIH HHS
  • NCRR NIH HHS

Zitieren

APA

Wanis, K. N., Kuerer, H. M., Sun, S. X., Hunt, K. K., Glencer, A. C., Teshome, M., Lucci, A., Weiser, R., Johnson, H., Smith, B. D., Gutierrez, A. M., Shaitelman, S. F., & Arun, B. K. (2024). Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Network Open, 7(6), e2418486. https://doi.org/10.1001/jamanetworkopen.2024.18486

Vancouver

Wanis KN, Kuerer HM, Sun SX, Hunt KK, Glencer AC, Teshome M, et al. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Network Open. 2024;7(6):e2418486. doi:10.1001/jamanetworkopen.2024.18486

BibTeX
@article{Wanis2024,
  author = {Wanis, Kerollos Nashat and Kuerer, Henry M and Sun, Susie X and Hunt, Kelly K and Glencer, Alexa C and Teshome, Mediget and Lucci, Anthony and Weiser, Roi and Johnson, Helen and Smith, Benjamin D and Gutierrez, Angelica M and Shaitelman, Simona F and Arun, Banu K},
  title = {Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {6},
  pages = {e2418486},
  doi = {10.1001/jamanetworkopen.2024.18486}
}
Kostenlos starten →